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Patients treated with intravitreal triamcinolone acetonide
The paper by Kocabora and coworkers (2008) underlines the message that patients 
treated with intravitreal triamcinolone acetonide are at risk of increased intraocular 
pressure (IOP) even after the clearance period of the drug. Furthermore, the develop-
ment of intractable secondary glaucoma requiring surgical intervention is clear advice 
to monitor these patients carefully.
However, the study was performed in the period 2003–2006, before the prescribing 
information for the drug changed in 2007. The new information states that the intravitreal 
use of triamcinolone acetonide is not suggested because the high risk of complications, 
particularly because of the increase of IOP. After this modiﬁ  cation, intravitreal triam-
cinolone acetonide is now an against-label and no more an off-label drug.
Currently, other drugs based on triamcinolone from different producers can be 
injected in vitreous. A recently introduced micronized gel triamcinolone (on-label for 
vitreous staining during vitreoretinal surgery) if used for intravitreal therapy (AMD, 
Myopia, Diabetes, CRVO/BRVO) is also correlated with increased IOP increase and 
can lead to ﬁ  ltering surgery in more than 50% of patients. In these cases the ﬁ  ltering 
surgery is frequently ineffective, leading to valve surgery in more than 25% of all 
cases. It must be underlined that this intravitreal use is absolutely off-label and that 
micronized triamcinolone is not a drug, but a surgical device.
To remain adherent to the on-label indications (veriﬁ  ed by GCP trials) is mandatory 
for routine therapy. The European Commission document for “'Detailed guidance on 
the collection, veriﬁ  cation and presentation of adverse reaction reports arising from 
clinical trials on medicinal products for human use, April 2004” is a useful guide to 
communicate these adverse reactions to the central national/supranational Agency 
(EMEA, FDA).
Pharmacovigilance is always important and the Ophthalmological Community 
must continue to be aware of the potential harm of these important drugs.
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We agree with them on the importance of pharmacovigilance and of warning the 
ophthalmology community about the potential risks of intravitreal triamcinolone 
(IVTA). We should always follow the principle of primum, non nocere in our medi-
cal practices. On the other hand, if we consider that the therapeutic effect of IVTA Clinical Ophthalmology 2008:2(2) 484
Gallenga and Lobefalo
is almost ‘miraculous’ in select cases, then we also feel 
obligated to offer our patients the beneﬁ  t of this treatment 
until a safer and effective alternative becomes available. This 
dilemma originates from the nature of our profession. Our 
main responsibilities are to inform our patients and obtain 
their consent for treatment by off-label use of trimancin-
oloneD and also to evaluate the risk-beneﬁ  t ratio for each 
individual patient and eye, which is a prerequisite in selecting 
candidates for IVTA.
We do not think that off-label use of triamcinolone 
should be considered illicit; many well known drugs are 
used off-label in routine ophthalmological practice, includ-
ing mitomycin-C (adjunct to trabeculectomy), cefuroxime 
(intracameral), and vancomycin (intravitreal), etc. Moreover, 
many approved drugs carry the risk of serious side effects 
with on-label use.
Steroid use in general comes with serious side effects 
regardless of the disease and administration route. Sec-
ondary intraocular pressure (IOP) elevation is observed 
even with approved uses of steroids such as ocular topical 
and systemic (oral and parenteral) uses. For that reason 
we do not consider IOP elevation to be a speciﬁ  c side 
effect of triamcinolone, although there is no doubt that 
the administration site exacerbates it. On the other hand, 
the retinal toxicity of preserved triamcinolone has been 
demonstrated in animal studies; hence, this toxicity can 
be avoided by use of a preservative-free triamcinolone 
formulation.
In conclusion, based on scientiﬁ  c rationale and guided by 
the results of medical studies, we believe that triamcinolone 
has become the de facto standard for treatment of certain 
edematous, inﬂ  ammatory, and neovascular eye diseases as 
an off-label drug, but we also agree that its use should be 
limited according to precisely determined criteria
Reference
Kocabora MS, Yilmazli C, Taskapili M, et al. 2008. Development of ocular 
hypertension and persistent glaucoma after intravitreal injection of 
triamcinolone. Clin Ophthalmol, 2:167–71.